Should Value Investors Buy Envista (NVST) Stock?

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.

Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.

Envista (NVST) is a stock many investors are watching right now. NVST is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A.

Investors should also note that NVST holds a PEG ratio of 1.05. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NVST's PEG compares to its industry's average PEG of 1.92. Over the past 52 weeks, NVST's PEG has been as high as 2.68 and as low as 0.90, with a median of 1.13.

Another notable valuation metric for NVST is its P/B ratio of 1.11. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.35. Over the past year, NVST's P/B has been as high as 1.30 and as low as 0.82, with a median of 1.08.

Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. NVST has a P/S ratio of 1.33. This compares to its industry's average P/S of 1.63.

If you're looking for another solid Medical - Products value stock, take a look at Phibro Animal Health (PAHC). PAHC is a Zacks Rank of #2 (Buy) stock with a Value score of A.

Shares of Phibro Animal Health are currently trading at a forward earnings multiple of 15.37 and a PEG ratio of 1.20 compared to its industry's P/E and PEG ratios of 16.19 and 1.92, respectively.

PAHC's Forward P/E has been as high as 16.56 and as low as 7.98, with a median of 12.28. During the same time period, its PEG ratio has been as high as 1.74, as low as 0.30, with a median of 0.50.

Furthermore, Phibro Animal Health holds a P/B ratio of 5.66 and its industry's price-to-book ratio is 2.35. PAHC's P/B has been as high as 5.85, as low as 2.52, with a median of 3.67 over the past 12 months.

These are just a handful of the figures considered in Envista and Phibro Animal Health's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that NVST and PAHC is an impressive value stock right now.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research